ResMed Q4 FY26 GAAP diluted EPS rises 2% to $2.64; revenue increases 9% to $1.46 billion
Reuters2026/08/06 20:36- ResMed Q4 FY2026 revenue rose 9% to USD 1.46 billion from June 30, 2025 period; GAAP diluted EPS increased 2% to USD 2.64.
- GAAP operating income slipped 1% to USD 448.71 million; GAAP gross margin narrowed 2 percentage points to 58.8%.
- Non-GAAP diluted EPS climbed 16% to USD 2.95; non-GAAP gross margin widened 0.9 percentage points to 62.3%.
- FY2026 revenue increased 10% to USD 5.65 billion; GAAP diluted EPS rose 10% to USD 10.43.
- Guided to more than USD 1.85 billion of shareholder returns in FY2027; raised quarterly dividend 10% to USD 0.66.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Crude oil is "coming back", but refined oil is "not coming back"; the global refining gap is widening.
According to Goldman Sachs, global refined oil exports have declined by about 6 million barrels per day year-on-year, with the Gulf region and Russia contributing three-quarters of the decrease. Unlike crude oil, which can be rerouted, damaged refineries cannot be relocated, and the Gulf region's refined oil exports have only recovered to 40% of pre-war levels. Goldman Sachs expects global refinery utilization rates to recover only by the second half of 2027; based on this, it has more than doubled its forecast for diesel profit margins in 2027.
Data: Detected an outflow of 35.11 million USDT from a certain exchange
SK Hynix CEO: Memory chip shortage will persist until 2030
Crypto prices
More
